113 related articles for article (PubMed ID: 15737628)
41. Development of the bovine immunodeficiency-like virus as a model of lentivirus disease.
Gonda MA; Oberste MS; Garvey KJ; Pallansch LA; Battles JK; Pifat DY; Bess JW; Nagashima K
Dev Biol Stand; 1990; 72():97-110. PubMed ID: 2178134
[TBL] [Abstract][Full Text] [Related]
42. In vitro detection of bovine immunodeficiency-like virus using monoclonal antibodies generated to a recombinant gag fusion protein.
Wannemuehler Y; Isaacson J; Wannemuehler M; Wood C; Roth JA; Carpenter S
J Virol Methods; 1993 Sep; 44(1):117-127. PubMed ID: 7693743
[TBL] [Abstract][Full Text] [Related]
43. Mutational analysis of the membrane proximal heptad repeat of the newcastle disease virus fusion protein.
McGinnes LW; Sergel T; Chen H; Hamo L; Schwertz S; Li D; Morrison TG
Virology; 2001 Oct; 289(2):343-52. PubMed ID: 11689056
[TBL] [Abstract][Full Text] [Related]
44. Biochemical, biophysical and preliminary X-ray crystallographic analyses of the fusion core of Sendai virus F protein.
Wang X; Xu Y; Cole DK; Lou Z; Liu Y; Rao Z; Wang M; Gao GF
Acta Crystallogr D Biol Crystallogr; 2004 Sep; 60(Pt 9):1632-5. PubMed ID: 15333939
[TBL] [Abstract][Full Text] [Related]
45. Mutations of conserved glycine residues within the membrane-spanning domain of human immunodeficiency virus type 1 gp41 can inhibit membrane fusion and incorporation of Env onto virions.
Miyauchi K; Curran R; Matthews E; Komano J; Hoshino T; Engelman DM; Matsuda Z
Jpn J Infect Dis; 2006 Apr; 59(2):77-84. PubMed ID: 16632906
[TBL] [Abstract][Full Text] [Related]
46. A viral transmembrane recombinant protein-based enzyme-linked immunosorbent assay for the detection of bovine immunodeficiency virus infection.
Abed Y; Archambault D
J Virol Methods; 2000 Mar; 85(1-2):109-16. PubMed ID: 10716344
[TBL] [Abstract][Full Text] [Related]
47. Seroprevalence and field isolation of bovine immunodeficiency virus.
Meas S; Kabeya H; Yoshihara S; Ohashi K; Matsuki S; Mikami Y; Sugimoto C; Onuma M
J Vet Med Sci; 1998 Nov; 60(11):1195-202. PubMed ID: 9853299
[TBL] [Abstract][Full Text] [Related]
48. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
Gustchina E; Hummer G; Bewley CA; Clore GM
J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
[TBL] [Abstract][Full Text] [Related]
49. Design and synthesis of membrane fusion inhibitors against the feline immunodeficiency virus.
Oishi S; Kodera Y; Nishikawa H; Kamitani H; Watabe T; Ohno H; Tochikura T; Shimane K; Kodama E; Matsuoka M; Mizukoshi F; Tsujimoto H; Fujii N
Bioorg Med Chem; 2009 Jul; 17(14):4916-20. PubMed ID: 19541488
[TBL] [Abstract][Full Text] [Related]
50. Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites.
He Y; Vassell R; Zaitseva M; Nguyen N; Yang Z; Weng Y; Weiss CD
J Virol; 2003 Feb; 77(3):1666-71. PubMed ID: 12525600
[TBL] [Abstract][Full Text] [Related]
51. Crystal structures of Nipah and Hendra virus fusion core proteins.
Lou Z; Xu Y; Xiang K; Su N; Qin L; Li X; Gao GF; Bartlam M; Rao Z
FEBS J; 2006 Oct; 273(19):4538-47. PubMed ID: 16972940
[TBL] [Abstract][Full Text] [Related]
52. The antibodies directed against N-terminal heptad-repeat peptide of hRSV fusion protein and its analog-5-Helix inhibit virus infection in vitro.
Ni L; Zhao L; Gao GF; Qian Y; Tien P
Biochem Biophys Res Commun; 2005 Jun; 331(4):1358-64. PubMed ID: 15883025
[TBL] [Abstract][Full Text] [Related]
53. Mutations at the C-terminus of the simian immunodeficiency virus envelope glycoprotein affect gp120-gp41 stability on virions.
Affranchino JL; González SA
Virology; 2006 Mar; 347(1):217-25. PubMed ID: 16380144
[TBL] [Abstract][Full Text] [Related]
54. Conformational Differences between Functional Human Immunodeficiency Virus Envelope Glycoprotein Trimers and Stabilized Soluble Trimers.
Castillo-Menendez LR; Nguyen HT; Sodroski J
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429345
[TBL] [Abstract][Full Text] [Related]
55. Fusion intermediates of HIV-1 gp41 as targets for antibody production: design, synthesis, and HR1-HR2 complex purification and characterization of generated antibodies.
Mzoughi O; Gaston F; Granados GC; Lakhdar-Ghazal F; Giralt E; Bahraoui E
ChemMedChem; 2010 Nov; 5(11):1907-18. PubMed ID: 20922745
[TBL] [Abstract][Full Text] [Related]
56. Characterization of HCoV-229E fusion core: implications for structure basis of coronavirus membrane fusion.
Liu C; Feng Y; Gao F; Zhang Q; Wang M
Biochem Biophys Res Commun; 2006 Jul; 345(3):1108-15. PubMed ID: 16714001
[TBL] [Abstract][Full Text] [Related]
57. Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus.
Sun Y; Zhang H; Shi J; Zhang Z; Gong R
Viruses; 2017 Sep; 9(9):. PubMed ID: 28906430
[TBL] [Abstract][Full Text] [Related]
58. Buried polar interactions and conformational stability in the simian immunodeficiency virus (SIV) gp41 core.
Ji H; Bracken C; Lu M
Biochemistry; 2000 Feb; 39(4):676-85. PubMed ID: 10651632
[TBL] [Abstract][Full Text] [Related]
59. A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1.
Cai L; Gochin M
Antimicrob Agents Chemother; 2007 Jul; 51(7):2388-95. PubMed ID: 17452484
[TBL] [Abstract][Full Text] [Related]
60. Structural characterization of the human respiratory syncytial virus fusion protein core.
Zhao X; Singh M; Malashkevich VN; Kim PS
Proc Natl Acad Sci U S A; 2000 Dec; 97(26):14172-7. PubMed ID: 11106388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
